var data={"title":"Ribavirin (oral inhalation): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ribavirin (oral inhalation): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/791140?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ribavirin-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ribavirin (oral inhalation): Patient drug information&quot;</a> and <a href=\"topic.htm?path=ribavirin-oral-inhalation-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ribavirin (oral inhalation): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623568\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Use of ribavirin in patients requiring mechanical ventilator assistance should be undertaken only by health care providers and support staff familiar with this mode of administration and the specific ventilator being used. Strict attention must be paid to procedures that have been shown to minimize the accumulation of drug precipitate, which can result in mechanical ventilator dysfunction and associated increases in pulmonary pressures.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Sudden deterioration of respiratory function has been associated with the initiation of ribavirin use in infants. Carefully monitor respiratory function during treatment. If the initiation of ribavirin treatment appears to produce sudden deterioration of respiratory function, stop treatment and reinstitute only with extreme caution, continuous monitoring, and consideration of coadministration of bronchodilators.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Aerosolized ribavirin is not indicated for use in adults. Be aware that ribavirin has been shown to produce testicular lesions in rodents and to be teratogenic in all animal species in which adequate studies have been conducted (rodents and rabbits).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623576\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Virazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623577\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Virazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623581\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiviral Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623632\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>RSV infection in hematopoietic cell or heart/lung transplant recipients (off-label use):</b>  Aerosol inhalation: RSV infection in hematopoietic cell or heart/lung transplant recipients (off-label use):  2 g (over 2 hours) every 8 hours (Boeckh 2007; Liu 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Heart/lung transplant recipients also received IVIG, methylprednisolone and palivizumab. Dosage and protocol may be institution specific. (Boeckh 2007; Chemaly 2006; Liu 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623631\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ribavirin-oral-inhalation-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ribavirin (oral inhalation): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>RSV infection:</b> <b>Note:</b> Due to potential toxic effects of exposed healthcare workers and variable efficacy results in trials, the AAP recommends against routine use of ribavirin to treat RSV; use should be reserved for patients with documented, potentially life-threatening disease (<i>Red Book</i> [AAP 2015]). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants and Children: Aerosol inhalation: Use with Viratek small particle aerosol generator (SPAG-2). <b>Note:</b> Dose actually delivered to the patient will depend on patient's minute ventilation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous aerosolization: 6 g administered over 12 to 18 hours/day for 3 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent aerosolization: 2 g over 2 hours 3 times daily in nonmechanically ventilated patients for 3 to 7 days has been used to permit easier accessibility for patient care and limit environmental exposure of healthcare worker. Due to apparent increased potential for crystallization of the high-dose 60 mg/mL solution around areas of turbulent flow such as bends in tubing or connector pieces, use of high-dose therapy in individuals with an endotracheal tube in place is not recommended (Englund 1994).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623633\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623634\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623635\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623649\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 6 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Inhalation [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Virazole: 6 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623579\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623638\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Inhalation: Ribavirin should be administered in well-ventilated rooms (at least 6 air changes/hour). In mechanically-ventilated patients, ribavirin can potentially be deposited in the ventilator delivery system depending on temperature, humidity, and electrostatic forces; this deposition can lead to malfunction or obstruction of the expiratory valve, resulting in inadvertently high positive end-expiratory pressures. The use of one-way valves in the inspiratory lines, a breathing circuit filter in the expiratory line, and frequent monitoring and filter replacement have been effective in preventing these problems. Solutions in SPAG-2 unit should be discarded at least every 24 hours and when the liquid level is low before adding newly reconstituted solution. Should not be mixed with other aerosolized medication. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133471\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator) for preparation; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a powder or solution for inhalation or an aerosol treatment; if there is potential for inhalation, respiratory protections is recommended (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623585\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">\n      <b>Respiratory syncytial virus:</b> Treatment of hospitalized infants and young children  with respiratory syncytial virus (RSV) infections; specially indicated for treatment of severe lower respiratory tract RSV infections in patients with an underlying compromising condition (prematurity, cardiopulmonary disease, or immunosuppression)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623586\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Treatment for RSV in adult hematopoietic stem cell or heart/lung  transplant recipients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623569\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ribavirin may be confused with riboflavin, rifAMPin, Robaxin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623597\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bigeminy, bradycardia, chest pain, hypotension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Apnea, atelectasis, bacterial pneumonia, bronchospasm, cyanosis, dyspnea, hypoventilation, pneumothorax, pulmonary complications (ventilator dependence), pulmonary edema, severe dyspnea (worsening of respiratory status)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anemia, hemolytic anemia, reticulocytosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623594\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Hypersensitivity to ribavirin or any component of the formulation; women who are pregnant or may become pregnant</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623595\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory deterioration:<b> [US Boxed Warning]: Sudden respiratory deterioration has been observed during the initiation of aerosolized ribavirin in infants; carefully monitor during treatment. If deterioration of respiratory function occurs, stop treatment; reinstitute with extreme caution, continuous monitoring, and consider concomitant administration of bronchodilators.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pregnancy: <b>[US Boxed Warning]: Significant teratogenic and/or embryocidal effects have been observed in all animal species with adequate studies. Use is contraindicated in pregnant women.</b> The manufacturer recommends that pregnant health care workers take precautions to limit exposure to ribavirin aerosol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Inhalation: <b>[US Boxed Warning]: Use with caution in patients requiring assisted ventilation because precipitation of the drug in the respiratory equipment may interfere with safe and effective patient ventilation; sudden deterioration of respiratory function has been observed;</b> monitor carefully in patients with COPD and asthma for deterioration of respiratory function. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623604\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623601\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=105699&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: Ribavirin (Oral Inhalation) may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. Specifically, concentrations of potentially myelotoxic methylated metabolites may be increased, while concentrations of active 6-thioguanine nucleotides may be decreased.  Management: Consider using alternative agent(s) when possible.  When these drugs are used in combination, monitor patients extra closely for signs/symptoms of myelosuppression.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Ribavirin (Oral Inhalation) may enhance the adverse/toxic effect of Didanosine. Ribavirin (Oral Inhalation) may increase serum concentrations of the active metabolite(s) of Didanosine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Interferons (Alfa): May enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Hemolytic anemia has been observed.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: May enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Specifically, the risk/severity of anemia may be increased. Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended. Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623590\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623591\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in females who are or may become pregnant.<b> [US Boxed Warning]: Significant teratogenic and/or embryocidal effects have been observed in all animal species with adequate studies.</b> The manufacturer recommends that pregnant health care workers take precautions to limit exposure to ribavirin aerosol; potential occupational exposure may be greatest if administration is via oxygen tent or hood, and lower if administered via mechanical ventilation. The minimum interval following exposure to ribavirin inhalation prior to pregnancy is not known. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623592\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ribavirin is excreted in breast milk. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623641\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Respiratory function, hemoglobin, reticulocyte count, CBC with differential, I &amp; O </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623614\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits replication of RNA and DNA viruses; inhibits influenza virus RNA polymerase activity and inhibits the initiation and elongation of RNA fragments resulting in inhibition of viral protein synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623617\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Inhalation: Systemic; dependent upon respiratory factors and method of drug delivery; maximal absorption occurs with the use of aerosol generator via endotracheal tube; highest concentrations in respiratory tract and erythrocytes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Occurs intracellularly and may be necessary for drug action; metabolized hepatically to deribosylated ribavirin (active metabolite) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 64% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory tract secretions: Infants and Children 6 weeks to 7 years: ~2 hours (Englund 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plasma: Infants and Children: Inhalation: 9.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Inhalation: At end of inhalation period</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Inhalation: Urine (40% as unchanged drug and metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623651\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ribavirin Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 g (1): $27,600.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Virazole Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 g (1): $29,953.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45855040\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Viramid (BR);</li>\n      <li>Virazide (AU);</li>\n      <li>Virazol (UA);</li>\n      <li>Virazole (BE, BR, DE, ES, GB, GR, IT, NL, SE, SG)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Reassessment of the Indications for Ribavirin Therapy in Respiratory Syncytial Virus Infections,&rdquo; <i>Pediatrics</i>, 1996, 97(1):137-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-oral-inhalation-drug-information/abstract-text/8545210/pubmed\" target=\"_blank\" id=\"8545210\">8545210</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Use of Ribavirin in the Treatment of Respiratory Syncytial Virus Infection,&rdquo; <i>Pediatrics</i>, 1993, 92(3):501-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-oral-inhalation-drug-information/abstract-text/8361820/pubmed\" target=\"_blank\" id=\"8361820\">8361820</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boeckh M, Englund J, Li Y, et al, &ldquo;Randomized Controlled Multicenter Trial of Aerosolized Ribavirin For Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic Cell Transplant Recipients,&rdquo; <i>Clin Infect Dis</i>, 2007, 44(2):245-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-oral-inhalation-drug-information/abstract-text/17173225/pubmed\" target=\"_blank\" id=\"17173225\">17173225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chemaly RF, Ghosh S, Bodey GP, et al, &ldquo;Respiratory Viral Infections in Adults With Hematologic Malignancies and Human Stem Cell Transplant Recipients: A Retrospective Study at a Major Cancer Center,&rdquo; <i>Medicine (Baltimore)</i>, 2006, 85(5):278-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-oral-inhalation-drug-information/abstract-text/16974212/pubmed\" target=\"_blank\" id=\"16974212\">16974212</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Englund JA, Piedra PA, Ahn YM, et al, &ldquo;High-Dose, Short-Duration Ribavirin Aerosol Therapy Compared With Standard Ribavirin Therapy in Children With Suspected Respiratory Syncytial Virus Infection,&rdquo; <i>J Pediatr</i>, 1994, 125:635-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-oral-inhalation-drug-information/abstract-text/7931890/pubmed\" target=\"_blank\" id=\"7931890\">7931890</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Englund JA, Piedra PA, Jefferson LS, Wilson SZ, Taber LH, Gilbert BE. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infectio<i>n. J Pediatr</i>. 1990;117(2 Pt 1):313-320.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-oral-inhalation-drug-information/abstract-text/2380833/pubmed\" target=\"_blank\" id=\"2380833\">2380833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu V, Dhillon GS, and Weill D, &ldquo;A Multi-Drug Regimen for Respiratory Syncytial Virus and Parainfluenza Virus Infections in Adult Lung and Heart-Lung Transplant Recipients,&rdquo; <i>Transp Infect Dis</i>, 2010, 12(1):38-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-oral-inhalation-drug-information/abstract-text/19761558/pubmed\" target=\"_blank\" id=\"19761558\">19761558</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meert KL, Sarnaik AP, Gelmini MJ, et al, &ldquo;Aerosolized Ribavirin in Mechanically Ventilated Children With Respiratory Syncytial Virus Lower Respiratory Tract Disease: A Prospective, Double-Blind, Randomized Trial,&rdquo; <i>Crit Care Med</i>, 1994, 22(4):566-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-oral-inhalation-drug-information/abstract-text/8143465/pubmed\" target=\"_blank\" id=\"8143465\">8143465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ottolini MG and Hemming VG, &ldquo;Prevention and Treatment Recommendations for Respiratory Syncytial Virus Infection. Background and Clinical Experience 40 Years After Discovery,&rdquo; <i>Drugs</i>, 1997, 54(6):867-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-oral-inhalation-drug-information/abstract-text/9421694/pubmed\" target=\"_blank\" id=\"9421694\">9421694</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith DW, Frankel LR, Mathers LH, et al, &ldquo;A Controlled Trial of Aerosolized Ribavirin in Infants Receiving Mechanical Ventilation for Severe Respiratory Syncytial Virus Infection,&rdquo; <i>N Engl J Med</i>, 1991, 325(1):24-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-oral-inhalation-drug-information/abstract-text/1904551/pubmed\" target=\"_blank\" id=\"1904551\">1904551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Bever HP, Desager KS, Van Hoeck K, et al, &ldquo;Water Intoxication After Nebulised Tribavirin,&rdquo; <i>Lancet</i>, 1995, 345(8947):451.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Virazole (ribavirin) [prescribing information]. Aliso Viejo, CA: Valeant Pharmaceuticals; August 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 105699 Version 34.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F45623568\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45623576\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F45623577\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F45623581\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F45623632\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F45623631\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F45623633\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F45623634\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F45623635\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45623649\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F45623579\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F45623638\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133471\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45623585\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F45623586\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45623569\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45623597\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45623594\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45623595\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45623604\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45623601\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F45623590\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45623591\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F45623592\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45623641\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45623614\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F45623617\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F45623651\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45855040\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/105699|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ribavirin-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">Ribavirin (oral inhalation): Patient drug information</a></li><li><a href=\"topic.htm?path=ribavirin-oral-inhalation-pediatric-drug-information\" class=\"drug drug_pediatric\">Ribavirin (oral inhalation): Pediatric drug information</a></li></ul></div></div>","javascript":null}